PROTAC based targeted degradation of LRG1 for mitigating corneal neovascularization.

• Tác giả: Hongzheng Bi, Yizhuo Geng, Duyin Jiang, Ya Jiao, Yongzheng Li, Yu Li, Huan Min, Guangjun Nie, Yingqiu Qi, Yongjun Qi, Bai Xue, Jingjuan Zhang, Furong Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 642.7 Table furnishings
• Thông tin xuất bản: Netherlands : Journal of controlled release : official journal of the Controlled Release Society , 2025
• Bộ sưu tập: NCBI
• ID: 680465

Tóm tắt

Leucine-rich alpha-2-glycoprotein 1 (LRG1), a secretory glycoprotein associated with angiogenesis, inflammation, fibrosis, and other pivotal pathophysiological processes, is significantly upregulated in corneal neovascularization (CNV), where it drives neovascularization via the TGF-β-Smad signaling pathway, making it a potential therapeutic target for CNV. This study employs proteolysis-targeting chimera (PROTAC) technology, utilizing our newly developed PROTAC agent,